Takeda Pharmaceutical Co (TKD) Stock Forecast & Price Target

9 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TKD Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Takeda

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TKD Stock 12 Month Forecast

Average Price Target

€36.46

▲(21.50% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Takeda Pharmaceutical Co in the last 3 months. The average price target is €36.46 with a high forecast of €38.21 and a low forecast of €33.91. The average price target represents a 21.50% change from the last price of €30.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","30":"€30","39":"€39","25.5":"€25.5","34.5":"€34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38.2122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.46305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€36.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.9066,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,25.5,30,34.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.63,30.29016923076923,30.95033846153846,31.610507692307692,32.27067692307692,32.930846153846154,33.59101538461539,34.25118461538462,34.911353846153844,35.57152307692308,36.23169230769231,36.89186153846154,37.55203076923077,{"y":38.2122,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.63,30.15561923076923,30.68123846153846,31.206857692307693,31.732476923076923,32.258096153846154,32.783715384615384,33.309334615384614,33.834953846153844,34.360573076923075,34.88619230769231,35.41181153846154,35.93743076923077,{"y":36.46305,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.63,29.95896923076923,30.28793846153846,30.61690769230769,30.94587692307692,31.274846153846152,31.603815384615384,31.932784615384612,32.261753846153844,32.59072307692308,32.91969230769231,33.24866153846153,33.577630769230765,{"y":33.9066,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.307,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.795,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.17,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.814,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.287,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.486,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.866,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.615,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.66,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.63,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€38.21

Average Price Target€36.46

Lowest Price Target€33.91

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Barker

Jefferies

€36.6→€38.21

Buy

27.33%

Upside

Reiterated

08/21/26

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Takeda Pharmaceutical Co (Other OTC: TKPHF)

Koichi Mamegano

Bank of America Securities

€32.29→€36.6

Buy

21.95%

Upside

Reiterated

08/13/26

Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

―

Hold

―

Reiterated

08/06/26

Takeda Pharmaceutical Co (TKPHF) Receives a Hold from Goldman Sachs

Miki Sogi

Bernstein

€37.14

Buy

23.74%

Upside

Assigned

07/07/26

Takeda Pharmaceutical Co (TKPHF) Receives a Buy from Bernstein

Shinichiro Muraoka

Morgan Stanley

€33.37→€33.91

Buy

12.98%

Upside

Reiterated

06/03/26

Takeda Pharmaceutical Co (TKPHF) Gets a Buy from Morgan Stanley

Unknown Analyst

Macquarie

Not Ranked

Macquarie

€27.99→€26.91

Buy

-10.33%

Downside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Barker

Jefferies

€36.6→€38.21

Buy

27.33%

Upside

Reiterated

08/21/26

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Takeda Pharmaceutical Co (Other OTC: TKPHF)

Koichi Mamegano

Bank of America Securities

€32.29→€36.6

Buy

21.95%

Upside

Reiterated

08/13/26

Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

―

Hold

―

Reiterated

08/06/26

Takeda Pharmaceutical Co (TKPHF) Receives a Hold from Goldman Sachs

Miki Sogi

Bernstein

€37.14

Buy

23.74%

Upside

Assigned

07/07/26

Takeda Pharmaceutical Co (TKPHF) Receives a Buy from Bernstein

Shinichiro Muraoka

Morgan Stanley

€33.37→€33.91

Buy

12.98%

Upside

Reiterated

06/03/26

Takeda Pharmaceutical Co (TKPHF) Gets a Buy from Morgan Stanley

Unknown Analyst

Macquarie

Not Ranked

Macquarie

€27.99→€26.91

Buy

-10.33%

Downside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Takeda Pharmaceutical Co

3 Months

Stephen BarkerJefferies

Success Rate

4/4 ratings generated profit

Average Return

+7.22%

Copying Stephen Barker's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +7.22% per trade.

1 Year

Koichi MameganoBank of America Securities

Success Rate

9/9 ratings generated profit

Average Return

+18.37%

Copying Koichi Mamegano's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.37% per trade.

2 Years

Koichi MameganoBank of America Securities

Success Rate

9/9 ratings generated profit

Average Return

+29.69%

Copying Koichi Mamegano's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TKD Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TKD has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TKD average Analyst price target in the past 3 months is 36.46.

Each month's total comprises the sum of three months' worth of ratings.

TKD Financial Forecast

TKD Earnings Forecast

Next quarter’s earnings estimate for TKD is €0.25 with a range of €0.24 to €0.25. The previous quarter’s EPS was €0.39. TKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TKD has Performed in-line its overall industry.

TKD Sales Forecast

Next quarter’s sales forecast for TKD is €6.26B with a range of €5.95B to €6.57B. The previous quarter’s sales results were €6.57B. TKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TKD has Performed in-line its overall industry.

TKD Stock Forecast FAQ

What is DE:TKD’s average 12-month price target, according to analysts?

Based on analyst ratings, Takeda Pharmaceutical Co Ltd’s 12-month average price target is 36.46.

What is DE:TKD’s upside potential, based on the analysts’ average price target?

Takeda Pharmaceutical Co Ltd has 21.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Takeda Pharmaceutical Co Ltd a Buy, Sell or Hold?

Takeda Pharmaceutical Co Ltd has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Takeda Pharmaceutical Co Ltd’s share price target?

The average share price target for Takeda Pharmaceutical Co Ltd is 36.46. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €38.21 ,and the lowest forecast is €33.91. The average share price target represents 21.50% Increase from the current price of €30.01.

What do analysts say about Takeda Pharmaceutical Co Ltd?

Takeda Pharmaceutical Co Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Takeda Pharmaceutical Co Ltd?

To buy shares of DE:TKD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Takeda Pharmaceutical Co (TKD) Stock Forecast & Price Target

TKD Analyst Ratings

TKD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Takeda Pharmaceutical Co

TKD Analyst Recommendation Trends

TKD Financial Forecast

TKD Earnings Forecast

TKD Sales Forecast

TKD Stock Forecast FAQ

Detailed List of Analyst Forecasts